{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:37:31Z","timestamp":1783535851267,"version":"3.55.0"},"reference-count":82,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1002\/pbc.26028","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T21:18:29Z","timestamp":1461273509000},"page":"1332-1338","source":"Crossref","is-referenced-by-count":64,"title":["Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia"],"prefix":"10.1002","volume":"63","author":[{"given":"Jill","family":"Samis","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology; Ann & Robert H. Lurie Children's Hospital of Chicago; Chicago Illinois"},{"name":"Department of Pediatrics; Northwestern University Feinberg School of Medicine; Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology Oncology; Ann & Robert H. Lurie Children's Hospital of Chicago; Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology; Ann & Robert H. Lurie Children's Hospital of Chicago; Chicago Illinois"},{"name":"Department of Pediatrics; Northwestern University Feinberg School of Medicine; Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Arceci","sequence":"additional","affiliation":[{"name":"Department of Child Health; The Ron Matricaria Institute of Molecular Medicine at Phoenix Children's Hospital; University of Arizona College of Medicine, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Oncology & Stem Cell Transplantation, Department of Pediatrics, Children's Hospital; Technical University of Dresden; Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Hijiya","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; Northwestern University Feinberg School of Medicine; Chicago Illinois"},{"name":"Division of Pediatric Hematology Oncology; Ann & Robert H. Lurie Children's Hospital of Chicago; Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,21]]},"reference":[{"key":"10.1002\/pbc.26028-BIB0001|pbc26028-cit-0001","unstructured":"Surveillance Research Program NCI http:\/\/seer.cancer.gov\/faststats\/"},{"key":"10.1002\/pbc.26028-BIB0002|pbc26028-cit-0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.23031","article-title":"Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group","volume":"57","author":"Champagne","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.26028-BIB0003|pbc26028-cit-0003","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.26028-BIB0004|pbc26028-cit-0004","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.26028-BIB0005|pbc26028-cit-0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2014.06.001","article-title":"Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia","volume":"28","author":"Mathisen","year":"2014","journal-title":"Blood Rev"},{"key":"10.1002\/pbc.26028-BIB0006|pbc26028-cit-0006","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1002\/pbc.26028-BIB0007|pbc26028-cit-0007","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: Clinical findings, management, and unanswered questions","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"10.1002\/pbc.26028-BIB0008|pbc26028-cit-0008","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1002\/pbc.26028-BIB0009|pbc26028-cit-0009","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1002\/pbc.26028-BIB0010|pbc26028-cit-0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.26028-BIB0011|pbc26028-cit-0011","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"},{"key":"10.1002\/pbc.26028-BIB0012|pbc26028-cit-0012","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pbc.22945","article-title":"Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy","volume":"56","author":"Hobernicht","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.26028-BIB0013|pbc26028-cit-0013","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000226288","article-title":"Does imatinib mesylate therapy cause growth hormone deficiency?","volume":"18","author":"Kebapcilar","year":"2009","journal-title":"Med Princ Pract"},{"key":"10.1002\/pbc.26028-BIB0014|pbc26028-cit-0014","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12185-008-0251-8","article-title":"Growth deceleration in a girl treated with imatinib","volume":"89","author":"Kimoto","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1002\/pbc.26028-BIB0015|pbc26028-cit-0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(08)61023-5","article-title":"Low bone density and decreased inhibin-B\/FSH ratio in a boy treated with imatinib during puberty","volume":"372","author":"Mariani","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/pbc.26028-BIB0016|pbc26028-cit-0016","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/pbc.24397","article-title":"Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis","volume":"60","author":"Narayanan","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.26028-BIB0017|pbc26028-cit-0017","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pbc.24121","article-title":"Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia","volume":"59","author":"Rastogi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.26028-BIB0018|pbc26028-cit-0018","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3324\/haematol.2009.008359","article-title":"Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib","volume":"94","author":"Schmid","year":"2009","journal-title":"Haematologica"},{"key":"10.1002\/pbc.26028-BIB0019|pbc26028-cit-0019","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"key":"10.1002\/pbc.26028-BIB0020|pbc26028-cit-0020","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1002\/pbc.26028-BIB0021|pbc26028-cit-0021","first-page":"522","volume-title":"Impairment of longitudinal growth by tyrosine kinase inhibitor (TKI) treatment-Data from a large pediatric cohort with chronic myeloid leukemia (CML)","volume":"124","author":"Tauer","year":"2014"},{"key":"10.1002\/pbc.26028-BIB0022|pbc26028-cit-0022","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/leu.2009.150","article-title":"Imatinib mesylate causes growth plate closure in vivo","volume":"23","author":"Vandyke","year":"2009","journal-title":"Leukemia"},{"key":"10.1002\/pbc.26028-BIB0023|pbc26028-cit-0023","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.3892\/mmr.2014.3074","article-title":"Inhibitory effects of imatinib on vitamin D3 synthesis in human keratinocytes","volume":"11","author":"Mehlig","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1002\/pbc.26028-BIB0024|pbc26028-cit-0024","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-0033-1343483","article-title":"TK inhibitor treatment disrupts growth hormone axis: Clinical observations in children with CML and experimental data from a juvenile animal model","volume":"225","author":"Ulmer","year":"2013","journal-title":"Klin Padiatr"},{"key":"10.1002\/pbc.26028-BIB0025|pbc26028-cit-0025","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(88)92147-2","article-title":"Leukaemia and growth hormone","volume":"1","author":"Frisch","year":"1988","journal-title":"Lancet"},{"key":"10.1002\/pbc.26028-BIB0026|pbc26028-cit-0026","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.2015-1002","article-title":"Risk of neoplasia in pediatric patients receiving growth hormone therapy-A report from the pediatric endocrine society drug and therapeutics committee","volume":"100","author":"Raman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/pbc.26028-BIB0027|pbc26028-cit-0027","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.ten.0000098611.49230.10","article-title":"Endocrinopathies in childhood cancer survivors","volume":"13","author":"Rose","year":"2003","journal-title":"Endocrinologist"},{"key":"10.1002\/pbc.26028-BIB0028|pbc26028-cit-0028","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1067\/S0022-3476(03)00246-4","article-title":"Update of guidelines for the use of growth hormone in children: The Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee","volume":"143","author":"Wilson","year":"2003","journal-title":"J Pediatr"},{"key":"10.1002\/pbc.26028-BIB0029|pbc26028-cit-0029","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1515\/JPEM.1993.6.1.79","article-title":"The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission-A preliminary report","volume":"6","author":"Zadik","year":"1993","journal-title":"J Pediatr Endocrinol"},{"key":"10.1002\/pbc.26028-BIB0030|pbc26028-cit-0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.leu.2404944","article-title":"Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis","volume":"22","author":"Brownlow","year":"2008","journal-title":"Leukemia"},{"key":"10.1002\/pbc.26028-BIB0031|pbc26028-cit-0031","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4161\/cc.4.7.1788","article-title":"Inhibition of c-FMS by imatinib: Expanding the spectrum of treatment","volume":"4","author":"Dewar","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1002\/pbc.26028-BIB0032|pbc26028-cit-0032","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity","volume":"551","author":"El Hajj Dib","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1002\/pbc.26028-BIB0033|pbc26028-cit-0033","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1002\/pbc.26028-BIB0034|pbc26028-cit-0034","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/jbmr.85","article-title":"The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo","volume":"25","author":"Vandyke","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1002\/pbc.26028-BIB0035|pbc26028-cit-0035","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate","volume":"115","author":"Vandyke","year":"2010","journal-title":"Blood"},{"key":"10.1002\/pbc.26028-BIB0036|pbc26028-cit-0036","first-page":"3034","article-title":"Approval summary: Imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors","volume":"8","author":"Dagher","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.26028-BIB0037|pbc26028-cit-0037","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2184.2007.00438.x","article-title":"Inhibition of platelet-derived growth factor receptor beta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro","volume":"40","author":"Fierro","year":"2007","journal-title":"Cell Prolif"},{"key":"10.1002\/pbc.26028-BIB0038|pbc26028-cit-0038","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00774-011-0323-3","article-title":"Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro","volume":"30","author":"Jonsson","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"10.1002\/pbc.26028-BIB0039|pbc26028-cit-0039","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.exphem.2008.12.008","article-title":"Effects of imatinib mesylate in osteoblastogenesis","volume":"37","author":"Tibullo","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1002\/pbc.26028-BIB0040|pbc26028-cit-0040","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.1002\/pbc.26028-BIB0041|pbc26028-cit-0041","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1210\/jc.2009-2057","article-title":"Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children","volume":"95","author":"Zemel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/pbc.26028-BIB0042|pbc26028-cit-0042","doi-asserted-by":"crossref","unstructured":"Tauer JT Hofbauer LC Jung R Gerdes S Glauche I Erben RG Suttorp M 2015 10 e0131192","DOI":"10.1371\/journal.pone.0131192"},{"key":"10.1002\/pbc.26028-BIB0043|pbc26028-cit-0043","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.26028-BIB0044|pbc26028-cit-0044","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism","volume":"355","author":"Grey","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.26028-BIB0045|pbc26028-cit-0045","first-page":"628","article-title":"Imatinib and altered bone and mineral metabolism","volume":"355","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.26028-BIB0046|pbc26028-cit-0046","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1210\/jc.2008-2324","article-title":"Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib","volume":"94","author":"O'Sullivan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/pbc.26028-BIB0047|pbc26028-cit-0047","doi-asserted-by":"crossref","first-page":"CR721","DOI":"10.12659\/MSM.883599","article-title":"Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment","volume":"18","author":"Jaeger","year":"2012","journal-title":"Med Sci Monit"},{"key":"10.1002\/pbc.26028-BIB0048|pbc26028-cit-0048","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/archpedi.158.6.531","article-title":"Prevalence of vitamin D deficiency among healthy adolescents","volume":"158","author":"Gordon","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1002\/pbc.26028-BIB0049|pbc26028-cit-0049","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid"},{"key":"10.1002\/pbc.26028-BIB0050|pbc26028-cit-0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","article-title":"Imatinib induces hypothyroidism in patients receiving levothyroxine","volume":"78","author":"Groot","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/pbc.26028-BIB0051|pbc26028-cit-0051","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1210\/jc.2011-1837","article-title":"Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport","volume":"97","author":"Braun","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/pbc.26028-BIB0052|pbc26028-cit-0052","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy","volume":"6","author":"Torino","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1002\/pbc.26028-BIB0053|pbc26028-cit-0053","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-0034-1372643","article-title":"Long-term imatinib treatment does not cause testicular toxicity in male adolescents with chronic myeloid leukemia and in a juvenile rat model","volume":"226","author":"Tauer","year":"2014","journal-title":"Klin Padiatr"},{"key":"10.1002\/pbc.26028-BIB0054|pbc26028-cit-0054","unstructured":"National Comprehensive Cancer Network http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp 2015."},{"key":"10.1002\/pbc.26028-BIB0055|pbc26028-cit-0055","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.leukres.2013.07.020","article-title":"Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor","volume":"37","author":"Zhou","year":"2013","journal-title":"Leuk Res"},{"key":"10.1002\/pbc.26028-BIB0056|pbc26028-cit-0056","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.26028-BIB0057|pbc26028-cit-0057","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2013-08-283580","article-title":"How I treat leukemia during pregnancy","volume":"123","author":"Milojkovic","year":"2014","journal-title":"Blood"},{"key":"10.1002\/pbc.26028-BIB0058|pbc26028-cit-0058","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","article-title":"Managing children with chronic myeloid leukaemia (CML): Recommendations for the management of CML in children and young people up to the age of 18 years","volume":"167","author":"la Fuente","year":"2014","journal-title":"Br J Haematol"},{"issue":"Suppl 2","key":"10.1002\/pbc.26028-BIB0059|pbc26028-cit-0059","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00277-015-2317-z","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"Palani","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1002\/pbc.26028-BIB0060|pbc26028-cit-0060","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"10.1002\/pbc.26028-BIB0061|pbc26028-cit-0061","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2008.01856.x","article-title":"Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction?","volume":"64","author":"Bilgir","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1002\/pbc.26028-BIB0062|pbc26028-cit-0062","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2012-4085","article-title":"Clinical review: Kinase inhibitors: Adverse effects related to the endocrine system","volume":"98","author":"Lodish","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/pbc.26028-BIB0063|pbc26028-cit-0063","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","article-title":"Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma","volume":"12","author":"Rock","year":"2007","journal-title":"Oncologist"},{"key":"10.1002\/pbc.26028-BIB0064|pbc26028-cit-0064","doi-asserted-by":"crossref","first-page":"R233","DOI":"10.1677\/ERC-10-0082","article-title":"Endocrine side effects of broad-acting kinase inhibitors","volume":"17","author":"Lodish","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1002\/pbc.26028-BIB0065|pbc26028-cit-0065","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1200\/JCO.2004.04.217","article-title":"Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment","volume":"22","author":"Breccia","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.26028-BIB0066|pbc26028-cit-0066","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM200503103521023","article-title":"Imatinib and regression of type 2 diabetes","volume":"352","author":"Veneri","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.26028-BIB0067|pbc26028-cit-0067","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1078155210378913","article-title":"Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice","volume":"17","author":"Agostino","year":"2011","journal-title":"J Oncol Pharm Pract"},{"key":"10.1002\/pbc.26028-BIB0068|pbc26028-cit-0068","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1182\/blood-2012-09-458463","article-title":"Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy","volume":"120","author":"Aduwa","year":"2012","journal-title":"Blood"},{"key":"10.1002\/pbc.26028-BIB0069|pbc26028-cit-0069","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00277-013-1752-y","article-title":"Imatinib induces body mass changes in women with chronic myeloid leukemia","volume":"92","author":"Breccia","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1002\/pbc.26028-BIB0070|pbc26028-cit-0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/JME-12-0003","article-title":"Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion","volume":"48","author":"Fitter","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"10.1002\/pbc.26028-BIB0071|pbc26028-cit-0071","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1096\/fj.06-6910com","article-title":"Amelioration of diabetes by imatinib mesylate (Gleevec): Role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning","volume":"21","author":"Hagerkvist","year":"2007","journal-title":"FASEB J"},{"key":"10.1002\/pbc.26028-BIB0072|pbc26028-cit-0072","doi-asserted-by":"crossref","first-page":"18895","DOI":"10.1073\/pnas.0810246105","article-title":"Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice","volume":"105","author":"Louvet","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/pbc.26028-BIB0073|pbc26028-cit-0073","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12185-012-1222-7","article-title":"Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin","volume":"97","author":"Ito","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1002\/pbc.26028-BIB0074|pbc26028-cit-0074","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.V116.21.3430.3430","article-title":"Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (Pts) with type 2 diabetes in the ENESTnd trial","volume":"116","author":"Saglio","year":"2010","journal-title":"Blood"},{"key":"10.1002\/pbc.26028-BIB0075|pbc26028-cit-0075","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00277-013-1769-2","article-title":"Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib","volume":"92","author":"Rosee","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1002\/pbc.26028-BIB0076|pbc26028-cit-0076","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1182\/blood-2013-01-480194","article-title":"Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia","volume":"121","author":"Russo","year":"2013","journal-title":"Blood"},{"key":"10.1002\/pbc.26028-BIB0077|pbc26028-cit-0077","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"10.1002\/pbc.26028-BIB0078|pbc26028-cit-0078","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00277-015-2318-y","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"94","author":"Rea","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1002\/pbc.26028-BIB0079|pbc26028-cit-0079","doi-asserted-by":"crossref","first-page":"e2014028","DOI":"10.4084\/mjhid.2014.028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Abruzzese","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1002\/pbc.26028-BIB0080|pbc26028-cit-0080","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2169\/internalmedicine.51.8314","article-title":"Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus","volume":"51","author":"Ono","year":"2012","journal-title":"Intern Med"},{"key":"10.1002\/pbc.26028-BIB0081|pbc26028-cit-0081","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/CMAR.S11948","article-title":"Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia","volume":"3","author":"Deremer","year":"2011","journal-title":"Cancer Manag Res"},{"issue":"Suppl:15s.","key":"10.1002\/pbc.26028-BIB0082|pbc26028-cit-0082","article-title":"Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies (abstract #6511)","volume":"28","author":"Talpaz","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.26028","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.26028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.26028\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T09:19:00Z","timestamp":1596100740000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/pbc.26028"}},"subtitle":["TKI-Associated Endocrinopathies in Pediatric CML"],"short-title":[],"issued":{"date-parts":[[2016,4,21]]},"references-count":82,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.26028","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4,21]]}}}